Search

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

Welcome to the Neuroscience Gallery | Boehringer Ingelheim US

Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.

Boehringer Ingelheim Office Hours

An Employee’s Commitment to Ensuring Access to Medicines

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

MERIAL: RECOMBITEK® Oral Bordetella Vaccine | Boehringer Ingelheim US

MERIAL, now part of Boehringer Ingelheim, grows canine vaccine portfolio with the introduction of the RECOMBITEK® Oral Bordetella vaccine.

Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’

First half 2019: High levels of investment in R&D and robust organic growth

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US

Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.

Phase III EMPA-KIDNEY trial will stop early

The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.

Investigational Compound Granted FDA Orphan Drug Designation

U.S. FDA Grants Orphan Drug Designation to Investigational Compound for Idiopathic Pulmonary Fibrosis

Championing for people with all abilities

Every diverse background brings unique perspectives to our company.

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease

Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

Heart Failure

My journey to advance diversity, equity and inclusion in the workplace

Hear from one of our employees, Tanisha Archer-Parkes, on the importance of diversity in the workplace and continuing to move toward a more inclusive and accepting society.

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

A Moment To Reflect on the Evolving Approach for Diabetes Management | Boehringer Ingelheim US

A Moment To Reflect on the Evolving Approach for Diabetes Management

Top-line Phase II Data for treatment of MASH

Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

Welcome to the Neuroscience Gallery | Boehringer Ingelheim US

Boehringer Ingelheim Office Hours

An Employee’s Commitment to Ensuring Access to Medicines

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

MERIAL: RECOMBITEK® Oral Bordetella Vaccine | Boehringer Ingelheim US

Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’

First half 2019: High levels of investment in R&D and robust organic growth

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US

Phase III EMPA-KIDNEY trial will stop early

Investigational Compound Granted FDA Orphan Drug Designation

Championing for people with all abilities

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease

Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases

Heart Failure

My journey to advance diversity, equity and inclusion in the workplace

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

A Moment To Reflect on the Evolving Approach for Diabetes Management | Boehringer Ingelheim US

Top-line Phase II Data for treatment of MASH